Shionogi Builds Women's Health And Sexual Health Portfolio With QuatRx Deal
This article was originally published in PharmAsia News
Executive SummaryThe U.S. subsidiary of Shionogi acquired global development and marketing rights to QuatRx Pharmaceuticals' selective estrogen receptor modulator ospemifene, building on the company's sexual medicine and women's health portfolio
You may also be interested in...
The first oral alternative to vaginal or oral steroidal estrogens for treatment of dyspareunia due to menopause appears to have lower risks of stroke and deep vein thrombosis, according to FDA labeling.